Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases

Emerging Data on Advanced Systemic Treatments for Children With AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

43 min

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Most Burdensome Symptoms Rated by PN Patients

Current systemic therapies have been shown to induce remission in a subset of AD patients

Can advanced systemic therapies modify pathomechanisms in AD?

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

23 min

ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

Barrier disruption in AD and the development of environmental and food allergies

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

What Could Remission Mean in AD?

The Risks of Associated Systemic and Atopic Comorbidities with AD

Factors Associated With Development of Atopic Comorbidities in AD

Can Early Intervention Shape the Course of Atopic Dermatitis?

8 min

Association of Younger Age of Onset With Persistence of AD

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

Infographic

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

6 min

videoanimation

Explore the Global Burden of Pediatric AD (PEDISTAD)

interactivity

Type 2 Inflammation in AD Manifestations in Skin and Body

6 min

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Can early intervention modify the course of AD?

Impact of Advanced Systemic Therapies on Disease Control in AD

6 min

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Guideline-Based Diagnosis of Atopic Dermatitis

interactivity

Type 2 Inflammation Within Skin Tissue in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

Diving Below the Surface of AD: The Role of Type 2 Inflammation

10 min

Considerations for Disease Modification in AD

The Role of Type 2 Inflammation in Moderate-to-Severe AD

Identification and Management of AD Uncontrolled With Topical Therapies in Children

Epidemiology and Pathophysiology of AD in Children

Current and Emerging Therapeutic Options for Children With Atopic Dermatitis

16 min

Atopic Dermatitis in Children: Not Just a Skin Disease

Type 2 Inflammation and Its Role in Atopic Dermatitis

Persistence of AD From Childhood Into Adulthood

Key Treatment Considerations for Management of Atopic Dermatitis in Children

Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Early Intervention and the Potential For Disease Modification in AD

Emerging Real-World Data on Advanced Systemic Therapies in AD

Learning objectives

Understand the role of type 2 inflammation in pathophysiology to guide treatment decisions

About these experts

MD, PhD

Donna Aline Culton

Professor of Dermatology Associate Director, Clinical Trials Unit Director, Clinical Immunofluorescence Laboratory  University of North Carolina, Chapel Hill Chapel Hill, NC, USA

MD, MS

Jason Hawkes

Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, OR and is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee

Lawrence F. Eichenfield

Vice Chair of the Department of Dermatology | University of California San Diego (UCSD) School of Medicine; Chief of Pediatric and Adolescent Dermatology | Rady Children’s Hospital San Diego, California, United States